Abstract: The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R1, R2, R3, R4, R5a, R5b, R5c and X are defined as in the description.
Type:
Grant
Filed:
December 19, 2016
Date of Patent:
April 9, 2019
Assignee:
SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Abstract: The present invention relates to a compound of Formula (I)-(IV) useful as ?-lactamase inhibitor, a pharmaceutically acceptable salt, ester, solvate or stereoisomer thereof, wherein R1, R2, M and ring A have definitions as those in the specification. The present invention further relates to methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and uses of these compounds. For example, the compounds of the present invention can be used as ?-lactamase inhibitors, for treatment and/or prophylaxis of diseases caused by bacterial infections, solving drug-resistance problems caused by ?-lactamases, especially bacterial drug-resistant diseases caused by type B metallo-?-lactamases.
Type:
Grant
Filed:
August 18, 2016
Date of Patent:
January 1, 2019
Assignees:
SUANZHU PHARMA CO., LTD., SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Abstract: The invention relates to a CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers; a pharmaceutical formulation, pharmaceutical composition and kit comprising said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers, and use of said CDK4/6 kinase inhibitor, or a pharmaceutically acceptable salt, ester, or solvate thereof, or their isomers. For example, the compounds of the invention are useful for reducing or inhibiting the activity of CDK4/6 kinase in a cell, and/or treating and/or preventing a cancer-related disease mediated by CDK4/6 kinase.
Type:
Grant
Filed:
September 14, 2017
Date of Patent:
April 24, 2018
Assignees:
XUANZHU PHARMA CO., LTD., SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Abstract: The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and/or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)
Type:
Grant
Filed:
March 11, 2016
Date of Patent:
March 13, 2018
Assignees:
SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD., XUANZHU PHARMA CO., LTD.